Clinical trials: Locally Advanced or, open to volunteers
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC
ALK TKIs, particularly second- and third-generation ALK TKIs, have significantly improved progression-free survival (PFS) in patients with advanced ALK-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT07671560
- Testing
- Combined group of ensatinib and arotinib
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Qiming Wang
HER2-positive Breast Cancer
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed…
- Trial name
- NCT04481932
- Testing
- Trastuzumab combined with Pyrotinib and chemotherapy
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Peking University
Advanced Cancer, Olanzapine
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal…
- Conditions
- Advanced Cancer, Olanzapine, Progression Free Survival
- Trial name
- NCT06338683
- Testing
- Olanzapine 2.5 MG, Standard anti-tumor treatment, Nutritional advice
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Qinghai Red Cross Hospital
Locally Advanced or Metastatic Solid Tumors
A Study of TYK-00540 in Adult Patients With Solid Tumors
The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.
- Trial name
- ASOTIAPWST (NCT06246071)
- Testing
- TYK-00540
- Where
- China
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- TYK Medicines, Inc
Breast Cancer (Locally Advanced or Metastatic), Healthy Volunteers (HV)
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer
The purpose of this research study is to test a new process for diagnosing breast cancer by examining changes to your DNA that can be detected from a blood test.
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), Healthy Volunteers (HV), Unhealthy Volunteers, Breast Cancer Screening
- Trial name
- NCT07374796
- Testing
- Epigenetic Assay
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
This clinical trial examines the acceptability and effect of a parenting support intervention for families coping with solid tumor that has spread to other places in the body (metastatic) or has come back (recurrent).
- Trial name
- NCT05059678
- Testing
- Best Practice, Educational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab…
- Trial name
- CONSOLIdATE-1 (NCT07048457)
- Testing
- Radical cystectomy
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Yale University
Advanced Melanoma and Normal or Impaired, Advanced Melanoma
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821…
- Trial name
- Asher-BioAB821 (NCT07027488)
- Testing
- AB821
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University